Synthetic peptide with triple agonist receptor activity Engineered for multi-receptor pathway research Research-grade · Lyophilized powder For in vitro receptor interaction studies only
For laboratory research use only. Not for human or veterinary consumption. SKU RT5.
The glucagon receptor is the differentiator. SM1 (GLP-1 only) and TR2 (GLP-1 + GIP) leave it untouched. But glucagon receptor activation drives energy expenditure through hepatic and thermogenic pathways that neither GLP-1 nor GIP can access. Preclinical data shows that adding this third receptor target to the dual GIP/GLP-1 framework produces the most pronounced effects on metabolic parameters of any approach studied to date. All three receptors are G-protein coupled and signal through cAMP/PKA cascades, but their tissue distribution and downstream effects are distinct. GLP-1 receptors dominate in the pancreas and hypothalamus. GIP receptors are concentrated in adipose tissue and the CNS. Glucagon receptors are heavily expressed in the liver. RT3 reaches all three tissue compartments.
| Classification | Triple GLP-1/GIP/Glucagon receptor agonist |
| Form | Lyophilized powder |
| Quantity | 5mg per vial |
Heritage Labs USA stocks all three tiers. SM1 is the selective GLP-1 agonist (31 amino acids, one receptor). TR2 is the dual GIP/GLP-1 agonist (39 amino acids, two receptors). RT3 is the triple agonist (three receptors). Comparative preclinical literature documents a clear stepwise increase in metabolic parameter engagement as you move from single to dual to triple activation.
Every Heritage Labs compound is manufactured to research-grade standards and shipped in protective packaging.
For laboratory research use only. Not for human or veterinary use.